pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium
NCT ID: NCT01785290
Last Updated: 2020-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1800 participants
INTERVENTIONAL
2013-06-30
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Two different dosages of haloperidol are used in this study to compare with placebo. A dosage of 1mg, or 2mg or placebo three times a day in a double-blinded fashion resulting in a three-armed multicentre randomized double-blinded placebo-controlled trial. To relate the potential beneficial effects of haloperidol to the a priori risk to develop delirium, the PREDELIRIC-model (delirium prediction model for ICU patients) will be used. This will enable the investigators to determine the preventive efficacy of haloperidol in patient groups based on their risk to develop delirium.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To assess patients for delirium using the Confusion Assessment Method (CAM)-ICU is part of daily clinical practice in all participating centres. In this study, high risk patients will receive three times a day a study drug of which two groups receive a low dose of haloperidol (1mg or 2mg) and a third arm will receive placebo.
This drug is worldwide the first choice of drug to treat delirious patients. When delirium is diagnosed, patients are treated according to delirium protocol, using a higher dosage than in the prophylactic treatment period as described in the study protocol. It is recognized that early treatment of delirium has beneficial effects compared with delayed treatment, and there is also some evidence that delirium prevention in ICU patients has beneficial effects, but the design of these previous studies was not optimal.
Potential side-effects of haloperidol include, extrapyramidal symptoms, drowsiness, agitation, and ventricular arrhythmias. The latter are extremely rare (only case-reports are published) and related to a higher dosage of haloperidol. With the dosage that will be used in the present study no relevant side-effects are anticipated. Nevertheless, and given the preventive nature of this study, extra attention is being paid on recognition of possible side-effects of haloperidol in the protocol. Importantly, in three recent prophylactic haloperidol studies no relevant side-effects, and in particular no ventricular arrhythmias, were reported using a similar low dosage of haloperidol as described in the present protocol.
During the study several inter-rater reliability checks (delirium experts versus ICU nurses) concerning the CAM\_ICU assessments will be performed. Also medical and nursing files will be checked to secure the quality of the delirium diagnose.
The study will be monitored (all sites), randomly included patient data will be checked on delirium diagnose and endpoints of the study. All data will be collected by Electronic CRF. A check of completeness on all data is build-in.
All variables are defined using a data dictionary (using the NICE data dictionary) supplemented with definitions of PREDELIRIC-model predictors, delirium diagnosis (at least one positive CAM-ICU assessment), and delirium duration.
Sample size calculation is based on the effect on number of days of survival in 28-days mortality derived from the evaluation study using low dosage of prophylactic haloperidol. If the true hazard ratio of control patients relative to intervention patients is 0.85, taken into account an accrual time of 90 days with 28 days of follow-up, the investigators will need to study 647 patients per intervention group and 647 control patients to be able to reject the null hypothesis that the experimental and control survival curves are equal with probability (power) 0.80. The Type I error probability associated with this test of this null hypothesis is 0.05. Taken into account a drop out of 10% the investigators will include 715 patients per group; in total 2145 patients. The investigators assume that the effect on number of days of survival in 28-days mortality will be comparable between the two intervention groups. The Cox-regression analysis group will have three levels (placebo, 1 mg and 2 mg haloperidol three times daily).
A Data Safety Monitoring Board (DSMB)will monitor the safety of the study including interim analyses on safety/futility after 175-350 and 500 patients and safety and superiority after 1000 patients. Followed by a final analysis after 2145 patients.
Only for the interim analysis after 500 and 1000 patients adjusting for covariates (age, gender, delirium prediction score and sepsis) will be performed to determine the effect on 28-day survival
This multicenter study will be performed in:
* Radboud University Nijmegen Medical Centre
* University Medical Centre Utrecht
* Medical Centre Leeuwarden (stopped January 2014)
* Onze Lieve Vrouwen Gasthuis, Amsterdam (stopped March 2015)
* Isala Clinic, Zwolle (stopped June 2014)
* Canisius Wilhelmina Ziekenhuis, Nijmegen
* Medisch Spectrum Twente, Enschede
* Gelre Hospital, Apeldoorn
* Atrium Medical Centre, Heerlen
* Jeroen Bosch Hospital, Den-Bosch
* Atrium Medical Centre, Heerlen
* Medical Centre Haaglanden (Westeinde and Antoniushove), Den-Haag
* Bronovo Hospital, Den-Haag
* St. Jansdal Hospital, Harderwijk
* Maxima Medical Centre, Veldhoven
* University Medical Centre, Groningen
* Amphia Hospital, Breda
* VieCuri Hospital, Venlo
* Scheper Hospital, Emmen (stopped August 2016)
* Diakonessenhuis Hospital, Utrecht
* Haga Hospital, Den-Haag
After the 4th interim analysis the DSMB advised to drop on study arm due to effectivity and efficiency reasons. Since July 2015 the study has been continued with two study arms and the included numbers of patients is adjusted to 1800 patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Haloperidol 1mg/q8h
Prophylactic haloperidol of 1 mg/q8h i.v.
Haloperidol 1 mg/q8h
Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
* aged ≥ 80 years
* weight ≤ 50 kg
* liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.
Haloperidol 2mg/q8h
Prophylactic haloperidol 2mg/q8h i.v.
Haloperidol 2 mg/q8h
Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
* aged ≥ 80 years
* weight ≤ 50 kg
* liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.
Sodium chloride 0.9%
Placebo (Sodium chloride 0.9%) three times a day
Placebo
Sodium Chloride 0.9%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Haloperidol 1 mg/q8h
Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
* aged ≥ 80 years
* weight ≤ 50 kg
* liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.
Haloperidol 2 mg/q8h
Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
* aged ≥ 80 years
* weight ≤ 50 kg
* liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.
Placebo
Sodium Chloride 0.9%
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* expected length of ICU stay of over one day
Exclusion Criteria
* patients admitted to the ICU for neurological reasons (including post-resuscitation patients)
* patients treated with other anti-psychotics
* prolonged QTc-time (\>500msec) or history of serious ventricular arrhythmia (in last 12 months)
* pregnancy/breast feeding
* delirious before ICU admission
* serious auditory or visual disorders
* ICU-stay ≤1 day
* unable to understand Dutch
* severely mentally disabled
* serious receptive aphasia
* moribund and not expected to survive 2 days
* known allergy to haloperidol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark van den Boogaard, PhD
Role: PRINCIPAL_INVESTIGATOR
Radboud University Nijmegen Medical Centre, Dept of Intensive Care Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radboud University Medical Centre
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Duprey MS, van den Boogaard M, van der Hoeven JG, Pickkers P, Briesacher BA, Saczynski JS, Griffith JL, Devlin JW. Association between incident delirium and 28- and 90-day mortality in critically ill adults: a secondary analysis. Crit Care. 2020 Apr 20;24(1):161. doi: 10.1186/s13054-020-02879-6.
Heesakkers H, Devlin JW, Slooter AJC, van den Boogaard M. Association between delirium prediction scores and days spent with delirium. J Crit Care. 2020 Aug;58:6-9. doi: 10.1016/j.jcrc.2020.03.008. Epub 2020 Mar 25.
van den Boogaard M, Slooter AJC, Bruggemann RJM, Schoonhoven L, Beishuizen A, Vermeijden JW, Pretorius D, de Koning J, Simons KS, Dennesen PJW, Van der Voort PHJ, Houterman S, van der Hoeven JG, Pickkers P; REDUCE Study Investigators; van der Woude MCE, Besselink A, Hofstra LS, Spronk PE, van den Bergh W, Donker DW, Fuchs M, Karakus A, Koeman M, van Duijnhoven M, Hannink G. Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. JAMA. 2018 Feb 20;319(7):680-690. doi: 10.1001/jama.2018.0160.
van den Boogaard M, Slooter AJ, Bruggemann RJ, Schoonhoven L, Kuiper MA, van der Voort PH, Hoogendoorn ME, Beishuizen A, Schouten JA, Spronk PE, Houterman S, van der Hoeven JG, Pickkers P. Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. Trials. 2013 Nov 21;14:400. doi: 10.1186/1745-6215-14-400.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-004012-66
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2012/424
Identifier Type: OTHER
Identifier Source: secondary_id
Delirium_Haldol-prophy
Identifier Type: -
Identifier Source: org_study_id